Palvella Therapeutics Inc... (PVLA)
NASDAQ: PVLA
· Real-Time Price · USD
22.59
-0.83 (-3.54%)
At close: Jun 17, 2025, 2:06 PM
Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases.
The company is based in Wayne, Pennsylvania.
Palvella Therapeutics Inc.
| Country | United States |
| IPO Date | Jan 2, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Wesley H. Kaupinen |
Contact Details
Address: 125 Strafford Avenue Wayne, Pennsylvania United States | |
| Website | https://palvellatx.com |
Stock Details
| Ticker Symbol | PVLA |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001583648 |
| CUSIP Number | 697947109 |
| ISIN Number | US6979471090 |
| Employer ID | 30-0784346 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director |
| Kathleen Goin | Chief Operating Officer |
| Matthew E. Korenberg | Chief Financial Officer & Treasurer |
| Bohan Wei | Vice President of Corporate Development & New Product Planning |
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer |
| Emily Cook | Senior Vice President of Clinical Operations |
| Jason Burdette | SVice President of CMC & Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 03, 2025 | 4 | Filing |
| Jun 03, 2025 | 3 | Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | 10-Q | Quarterly Report |